ACET News and Press, Adicet Bio Inc. From 10/07/25

2025-10-07 12:48:57 ET Adicet Bio, Inc. (ACET) ADI-001 Phase 1 Clinical Update Call Company Participants Chen Schor - CEO, President & Director Julie Maltzman - Chief Medical Officer Blake Aftab - Senior VP & Chief Scientific Officer ... Read the fu...

2025-10-07 12:35:19 ET Adicet Bio, Inc. - Special Call Company Participants Chen Schor - CEO, President & Director Julie Maltzman - Chief Medical Officer Blake Aftab - Senior VP & Chief Scientific Officer ... Read the full article on Seeking Alpha...

2025-10-07 07:13:10 ET More on Adicet Bio Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio Financial information for Adicet Bio Read the full article on Seeking Alpha For further details see: Adicet Bio lau...

Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten registered direct offering of 70,001,000 shares of...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven evaluable LN and SLE patients experienced rapid and sustained reductions in the Systemic Lup...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on September 30, 2025. One individual was hired by Adicet in September ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Gl...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 29, 2025. Two individuals were hired by Adicet in August 2025. ...

Adicet Bio Inc. (ACET) is expected to report $-0.32 for Q2 2025

2025-08-07 17:30:24 ET More on Adicet Bio Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio Financial information for Adicet Bio Read the full article on Seeking Alpha For further details see: Adicet Bio GAA...